DL-Homocysteine thiolactone hydrochloride (DL-Homocysteinethiolactone hydrochloride) is a cysteine derivative that binds to and induces conformational changes in various plasma proteins, slowing coagulation and inducing oxidative stress. It decreases left ventricular systolic blood pressure and cardiac force and induces seizures in vivo.

DL-Homocysteine thiolactone hydrochloride (DL-Hcy TLHC)的急性给药显著降低CF并部分降低心脏收缩力，证实了其心脏抑制作用。与DL-Hcy TLHC同时应用不同的重要心血管气体递质抑制剂表明，额外的HO-1抑制产生的效果比NOS或CSE抑制更为强大。CO产生的抑制显著增强了DL-Hcy TLHC对心动参数的影响，而NOS和CSE抑制仅影响CF。DL-Hcy TLHC与不同气体递质抑制剂的急性给药未显示出促氧化潜力[1]。

Only groups of hearts in which the CPP/CF relationship was studied twice in the absence of drugs were included in the study. After perfusion in the absence of any medication (control conditions), hearts were perfused with: 10?μM DL-Homocysteinethiolactone hydrochloride (DL-Hcy TLHC); 10?μM DL-Hcy TLHC + 30?μM L-NAME (N ω-Nitro-L-arginine methyl ester, an inhibitor of NOS); 10?μM DL-Hcy TLHC + 10?μM DL-PAG (DL-Propargylglycine, an inhibitor of cystathionine gamma lyase-CSE); 10?μM DL-Hcy TLHC + 10?μM ZnPPR IX (protoporphyrin IX zinc, an inhibitor of HO-1) and compared to the respective controls[1].